Oncotarget
Introducing Oncotarget |
https://doi.org/10.18632/oncotarget.101 Mikhail Blagosklonny, and Andrei Gudkov |
2 |
PDF | How to cite | Editorial | Order a Reprint |
Shape-shifting and tumor suppression by PLZF |
https://doi.org/10.18632/oncotarget.102 Robin M. Hobbs, and Pier Paolo Pandolfi |
3-5 |
PDF | How to cite | Order a Reprint |
Bortezomib: killing two birds with one stone in gastrointestinal stromal tumors |
https://doi.org/10.18632/oncotarget.103 Stefan Duensing, and Anette Duensing |
6-8 |
Abstract | PDF | How to cite | Order a Reprint |
Smooth muscle α-actin is a direct target of PLZF: effects on the cytoskeleton and on susceptibility to oncogenic transformation |
https://doi.org/10.18632/oncotarget.104 Jin Shi, Minghao Sun, and Peter K. Vogt |
9-21 |
Abstract | PDF | How to cite | Order a Reprint |
Over-expression of CKS1B activates both MEK/ERK and JAK/STAT3 signaling pathways and promotes myeloma cell drug-resistance |
https://doi.org/10.18632/oncotarget.105 Lei Shi, Siqing Wang, Maurizio Zangari, Hongwei Xu, Thai M. Cao, Chunjiao Xu, Yong Wu, Fang Xiao, Yinghong Liu, Ye Yang, Mohamed Salama, Guiyuan Li, Guido Tricot, and Fenghuang Zhan |
22-33 |
Abstract | PDF | How to cite | Order a Reprint |
Phase 2 clinical trial of 5-azacitidine, valproic acid, and all-trans retinoic acid in patients with high-risk acute myeloid leukemia or myelodysplastic syndrome |
https://doi.org/10.18632/oncotarget.106 Emmanuel Raffoux, Audrey Cras, Christian Recher, Pierre-Yves Boëlle, Adrienne de Labarthe, Pascal Turlure, Jean-Pierre Marolleau, Oumedaly Reman, Claude Gardin, Maud Victor, Sébastien Maury, Philippe Rousselot, Jean-Valère Malfuson, Odile Maarek, Marie-Thérèse Daniel, Pierre Fenaux, Laurent Degos, Christine Chomienne, Sylvie Chevret, and Hervé Dombret |
34-42 |
Abstract | PDF | How to cite | Order a Reprint |
The tumor suppressor p53 connects ribosome biogenesis to cell cycle control: a double-edged sword |
https://doi.org/10.18632/oncotarget.107 Michael Hölzel, Kaspar Burger, Bastian Mühl, Mathias Orban, Markus Kellner, and Dirk Eick |
43-47 |
Abstract | PDF | How to cite | Order a Reprint |
ID4: a new player in the cancer arena |
https://doi.org/10.18632/oncotarget.108 Stefania Dell’Orso, Federica Ganci, Sabrina Strano, Giovanni Blandino, and Giulia Fontemaggi |
48-58 |
Abstract | PDF | How to cite | Order a Reprint |
A critical role for the NFkB pathway in multiple myeloma |
https://doi.org/10.18632/oncotarget.109 Yulia N. Demchenko, and W. Michael Kuehl |
59-68 |
Abstract | PDF | How to cite | Order a Reprint |
Targeting TOR dependence in cancer |
https://doi.org/10.18632/oncotarget.110 Matthew R. Janes, and David A. Fruman |
69-76 |
Abstract | PDF | How to cite | Order a Reprint |
Copyright © 2021 Impact Journals, LLC
Impact Journals is a registered trademark of Impact Journals, LLC